Bioretec Ltd – Managers’ transactions

Bioretec Ltd      Managers’ transactions 5 January 2024 at 11.00 a.m. EET

Bioretec Oy - Managers' Transactions

__________________________________________

Person subject to the notification requirement

Name: Stephen Industries Inc Oy

Position: Closely associated person

(X) Legal person  (1):Person Discharging Managerial Responsibilities In Issuer

Name: Kustaa Poutiainen

Position: Member of the Board

Issuer: Bioretec Oy

LEI: 7437008736AG7HY51K13

Notification type: INITIAL NOTIFICATION

Reference number: 48652/4/6

____________________________________________

Transaction date: 2024-01-03

Outside a trading venue

Instrument type: SHARE

ISIN: FI4000480454

Nature of transaction: ACQUISITION

Transaction details

(1): Volume: 606370 Unit price: 2.1 EUR

Aggregated transactions (1):

Volume: 606370 Volume weighted average price: 2.1 EUR

Further enquiries

Timo Lehtonen, CEO, tel. +358 50 433 8493

Johanna Salko, CFO, tel. +358 40 754 8172

Certified adviser: Nordic Certified Adviser AB, +46 70 551 67 29

Information about Bioretec

Bioretec is a globally operating Finnish medical device company that continues to pioneer the Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. 

Bioretec is developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong biodegradable materials for enhanced surgical outcomes. The RemeOs™ implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. The first RemeOs™ product market authorization has been received in the U.S. in March 2023, and in Europe, CE mark is expected to be received during the first quarter of 2024. Bioretec is positioning itself to enter the addressable over USD 7 billion global orthopedic trauma market and to become a game changer in surgical bone fracture treatment.

Better healing – Better life. www.bioretec.com

Bioretec Ltd's schedule for financial reporting in 2024 and updates in the disclosure policy

Bioretec Ltd  Company announcement 11 December 2023 at 5:15 p.m. EET

In the future, in addition to the financial statements bulletin and half-year report, Bioretec will also publish business reviews for January–March and January–September. As a result, Bioretec Ltd has updated its disclosure policy describing the general principles and procedures that the company adheres to in its communication with capital markets and financial media.

The updated disclosure policy is available on the company’s web pages at https://bioretec.com/investors/investors-in-english/investor-relations/disclosure-policy

Bioretec Ltd’s schedule for financial reporting in 2024

In 2024, Bioretec will publish the following financial reports:

• financial statements bulletin for January–December 2023 on Friday 16 February 2024
• Annual Report for 2023 during week 11/2024 at the latest (week commencing on 11 March 2024)
• business review for January–March 2024 on Thursday 16 May 2024
• half-year report for January–June 2024 on Thursday 15 August 2024
• business review for January–September 2024 on Thursday 14 November 2024

The Annual Report includes the report of the Board of Directors, the consolidated financial statements, the parent company financial statements, and the auditor’s report for the financial period 1 January–31 December 2023.

The releases will be available online at Bioretec Ltd’s website at https://bioretec.com/investors/investors-in-english/reports-and-presentations.

Bioretec Ltd’s Annual General Meeting is planned to be held on Friday, 26 April 2024. The company's Board of Directors will convene the Annual General Meeting separately later.

Further enquiries

Timo Lehtonen, CEO, +358 50 433 8493
Johanna Salko, CFO, +358 40 754 8172

Certified adviser

Nordic Certified Adviser AB, +46 70 551 67 29

Information about Bioretec

Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. 

Bioretec is developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong biodegradable materials for enhanced surgical outcomes. The RemeOs™ implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. The first RemeOs™ product market authorization has been received in the U.S. in March 2023, and in Europe, CE mark is expected to be received during the first quarter of 2024. Bioretec is positioning itself to enter the addressable over USD 7 billion global orthopedic trauma market and to become a game changer in surgical bone fracture treatment.

Better healing – Better life. www.bioretec.com

Inside information: Bioretec´s Board of Directors to initiate a new CEO recruitment process

Bioretec Ltd   Inside information  16 November 2023 at 1.30 p.m. EEST

Bioretec Ltd, a pioneer of biodegradable orthopedic implants, is initiating a new CEO recruitment process as the company’s current CEO, Mr. Timo Lehtonen, shall transfer into a new role within the company. The Board of Directors and Mr. Lehtonen have reached a mutual consensus in good understanding, based on a shared vision for the company’s future, to begin a recruitment process for a new CEO who will steer Bioretec to its forthcoming growth stages. Mr. Lehtonen will maintain his role as CEO with the Board’s full support until the successor is appointed, ensuring stability and continuity in the leadership of the Company.

During Mr. Lehtonen’s tenure, Bioretec has reached numerous milestones, notably reforming the surgical treatment of bone fractures with biodegradable metal implants through a first-ever FDA market authorization of magnesium-based implants in the U.S., thus significantly improving patient recovery and quality of life. Furthermore, under his leadership, the Company has enhanced its international market reach with sustained double-digit (in percentages) revenue growth and solidified its status as an innovator in biodegradable technologies.

“It has been an honor to lead Bioretec since 2019, overseeing the company’s dynamic growth with unwavering commitment. I deem that this is an appropriate juncture for a new leader to continue to implement the Company’s vision. My deepest appreciation goes out to our executive team, the Board, and our knowledgeable staff, whose collaborative efforts have been integral to our successes in redefining bone fracture treatment and improving patients’ quality of life.”, says Timo Lehtonen, the CEO of Bioretec.

Mr. Tomi Numminen, Chairman of the Board states, “The Board expresses its gratitude to Mr. Timo Lehtonen for his strong leadership and dedication. As we proceed with the selection of a new CEO, our focus remains on securing a leader with profound expertise in driving international business growth in alignment with Bioretec’s strategic ambitions.”

Further enquiries

Tomi Numminen, Chairman of the Board, tel. +358 40 581 2132
 

Certified advisor

Nordic Certified Adviser AB, +46 70 551 67 29
 

Bioretec in brief
 

Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. 


Bioretec is developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong biodegradable materials for enhanced surgical outcomes. The RemeOs™ implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. The first RemeOs™ product market authorization has been received in the U.S. in March 2023, and in Europe, the CE-mark is expected to be received during the first quarter of 2024. Bioretec is positioning itself to enter the addressable USD 7 billion global orthopedic trauma market and become a game changer in surgical bone fracture treatment.

Better healing – Better life. www.bioretec.com

Bioretec Ltd – Managers’ transactions

Bioretec Ltd      Managers’ transactions 6 November 2023 at 10.00 a.m. EET

Bioretec Oy - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Timo Lehtonen

Position: Chief Executive Officer

 Issuer: Bioretec Oy

LEI: 7437008736AG7HY51K13

Notification type: INITIAL NOTIFICATION

Reference number: 42517/5/4

____________________________________________

Transaction date: 2023-11-01

Outside a trading venue

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

ISIN: FI4000480454

Nature of transaction: ACCEPTANCE OF A STOCK OPTION

Transaction details

(1): Volume: 100000 Unit price: 0 EUR

Aggregated transactions (1):

Volume: 100000 Volume weighted average price: 0 EUR

Further enquiries

Tomi Numminen, Chairman of the board, tel. +358 40 581 2132

Johanna Salko, CFO, tel. +358 40 754 8172

Certified adviser: Nordic Certified Adviser AB, +46 70 551 67 29

Information about Bioretec

Bioretec is a globally operating Finnish medical device company that continues to pioneer the Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. 

Bioretec is developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong biodegradable materials for enhanced surgical outcomes. The RemeOs™ implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. The first RemeOs™ product market authorization has been received in the U.S. in March 2023, and in Europe, CE mark is expected to be received during the first quarter of 2024. Bioretec is positioning itself to enter the addressable over USD 7 billion global orthopedic trauma market and to become a game changer in surgical bone fracture treatment.

Better healing – Better life. www.bioretec.com

Bioretec Ltd – Managers’ transactions

Bioretec Ltd      Managers’ transactions 6 November 2023 at 10.00 a.m. EET

Bioretec Oy - Managers' Transactions

____________________________________________

Person subject to the notification requirement

Name: Rami Ojala

Position: Other senior manager

 Issuer: Bioretec Oy

LEI: 7437008736AG7HY51K13

Notification type: INITIAL NOTIFICATION

Reference number: 42518/5/4

____________________________________________

Transaction date: 2023-11-01

Outside a trading venue

Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT

ISIN: FI4000480454

Nature of transaction: ACCEPTANCE OF A STOCK OPTION

Transaction details

(1): Volume: 67000 Unit price: 0 EUR

Aggregated transactions (1):

Volume: 67000 Volume weighted average price: 0 EUR

Further enquiries

Timo Lehtonen, CEO, tel. +358 50 433 8493

Johanna Salko, CFO, tel. +358 40 754 8172

Certified adviser: Nordic Certified Adviser AB, +46 70 551 67 29

Information about Bioretec

Bioretec is a globally operating Finnish medical device company that continues to pioneer the Bioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. 

Bioretec is developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong biodegradable materials for enhanced surgical outcomes. The RemeOs™ implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. The first RemeOs™ product market authorization has been received in the U.S. in March 2023, and in Europe, CE mark is expected to be received during the first quarter of 2024. Bioretec is positioning itself to enter the addressable over USD 7 billion global orthopedic trauma market and to become a game changer in surgical bone fracture treatment.

Better healing – Better life. www.bioretec.com